Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi to Cut 1,500-2,000 Jobs in France - Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2012 | 02:11pm CEST

French pharmaceutical giant Sanofi SA (SAN.FR, SNY) will disclose cuts of between 1,500 and 2,000 jobs in France on Sept. 25, French newspaper Le Figaro reported Saturday, without citing sources.

The company plans to reduce its 28,000 payroll in France mainly through attrition, the newspaper said.

In July, Sanofi had said it planned to cut jobs at two French units in a bid to preserve the company's profitability, which has been put at risk by recent patent expirations and the economic recession in most of Europe. The company had said it would detail the job cuts in September.

At the time, French Industry Minister Arnaud Montebourg had criticized the company and said he wouldn't tolerate when profitable companies slash jobs.

A Sanofi spokesman didn't return a phone call seeking comments.

Newspaper Web site: http://www.lefigaro.fr

Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05/25 SANOFI : Data on Influenza Described by Researchers at Sanofi (Passive enhanced ..
05/25 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Entry into a Material ..
05/25 SANOFI : FDA approves Sanofi and Regenerons Kevzara for adult rheumatoid arthrit..
05/24 SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/23 THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
05/23 SANOFI : s insulin lispro receives CHMP positive opinion to treat diabetes
05/23 SANOFI : Phony Veterinary Labels Land Michael Chihwen Wang in the Doghouse
05/22 SANOFI : and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Tre..
05/22 SANOFI SA : Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispr..
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 FDA chief says agency needs to play a role in constraining drug prices by eas..
05/24 Exelixis Could Still Be A Buy
05/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
05/23 What Happened With The Genzyme CVR Since August 2015
Advertisement
Financials (€)
Sales 2017 36 691 M
EBIT 2017 9 442 M
Net income 2017 7 526 M
Debt 2017 3 541 M
Yield 2017 3,42%
P/E ratio 2017 14,83
P/E ratio 2018 18,18
EV / Sales 2017 3,11x
EV / Sales 2018 2,99x
Capitalization 110 539 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI13.54%123 549
JOHNSON & JOHNSON10.69%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results